The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Alphagan P Ophthalmic solution, of AbbVie Inc. Brimonidine Tartrate Ophthalmic solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. According to IQVIA, Brimonidine Tartrate Ophthalmic solution, had an estimated market size of $97 million for twelve months ending December 2022. The pharma company said that it has a cumulative total of 180 ANDA approvals (156 final approvals and 24 tentative approvals) from USFDA. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world. The drug maker reported 29% drop in consolidated net profit to Rs 121.92 crore despite a 18.7% rise in net sales to Rs 1,509.02 crore in Q3 FY23 over Q3 FY22. Shares of Alembic Pharmaceuticals closed 2.07% lower at Rs 468.30 on Wednesday, 29 March 2023. Powered by Capital Market - Live News |